 Cytotoxicity, Immunologic
"Cytotoxicity, Immunologic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitized T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement.
| Descriptor ID |
D003602
|
| MeSH Number(s) |
G12.287
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Cytotoxicity, Immunologic".
Below are MeSH descriptors whose meaning is more specific than "Cytotoxicity, Immunologic".
This graph shows the total number of publications written about "Cytotoxicity, Immunologic" by people in this website by year, and whether "Cytotoxicity, Immunologic" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 2 | 2 | | 1995 | 1 | 2 | 3 | | 1996 | 3 | 1 | 4 | | 1997 | 1 | 2 | 3 | | 1998 | 2 | 3 | 5 | | 1999 | 0 | 3 | 3 | | 2000 | 4 | 3 | 7 | | 2001 | 4 | 2 | 6 | | 2002 | 0 | 2 | 2 | | 2003 | 0 | 4 | 4 | | 2004 | 0 | 5 | 5 | | 2005 | 1 | 3 | 4 | | 2006 | 0 | 6 | 6 | | 2007 | 0 | 5 | 5 | | 2008 | 0 | 3 | 3 | | 2009 | 2 | 4 | 6 | | 2010 | 0 | 6 | 6 | | 2011 | 0 | 2 | 2 | | 2012 | 1 | 2 | 3 | | 2013 | 1 | 3 | 4 | | 2014 | 1 | 2 | 3 | | 2015 | 2 | 2 | 4 | | 2016 | 2 | 3 | 5 | | 2017 | 0 | 1 | 1 | | 2018 | 1 | 4 | 5 | | 2019 | 0 | 5 | 5 | | 2020 | 1 | 1 | 2 | | 2021 | 0 | 2 | 2 | | 2023 | 0 | 1 | 1 | | 2024 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Cytotoxicity, Immunologic" by people in Profiles.
-
Yandamuri SS, Filipek B, Lele N, Cohen I, Bennett JL, Nowak RJ, Sotirchos ES, Longbrake EE, Mace EM, O'Connor KC. A Noncanonical CD56dimCD16dim/- NK Cell Subset Indicative of Prior Cytotoxic Activity Is Elevated in Patients with Autoantibody-Mediated Neurologic Diseases. J Immunol. 2024 Mar 01; 212(5):785-800.
-
Yandamuri SS, Filipek B, Obaid AH, Lele N, Thurman JM, Makhani N, Nowak RJ, Guo Y, Lucchinetti CF, Flanagan EP, Longbrake EE, O'Connor KC. MOGAD patient autoantibodies induce complement, phagocytosis, and cellular cytotoxicity. JCI Insight. 2023 06 08; 8(11).
-
Isola I, Bras?-Maristany F, Moreno DF, Mena MP, Oliver-Calders A, Par? L, Rodr?guez-Lobato LG, Martin-Antonio B, Cibeira MT, Blad? J, Rosi?ol L, Prat A, Lozano E, Fern?ndez de Larrea C. Gene Expression Analysis of the Bone Marrow Microenvironment Reveals Distinct Immunotypes in Smoldering Multiple Myeloma Associated to Progression to Symptomatic Disease. Front Immunol. 2021; 12:792609.
-
Ramaswamy A, Brodsky NN, Sumida TS, Comi M, Asashima H, Hoehn KB, Li N, Liu Y, Shah A, Ravindra NG, Bishai J, Khan A, Lau W, Sellers B, Bansal N, Guerrerio P, Unterman A, Habet V, Rice AJ, Catanzaro J, Chandnani H, Lopez M, Kaminski N, Dela Cruz CS, Tsang JS, Wang Z, Yan X, Kleinstein SH, van Dijk D, Pierce RW, Hafler DA, Lucas CL. Immune dysregulation and autoreactivity correlate with disease severity in SARS-CoV-2-associated multisystem inflammatory syndrome in children. Immunity. 2021 05 11; 54(5):1083-1095.e7.
-
Guth A, Monk E, Agarwal R, Bergman BC, Zemski-Berry KA, Minic A, Jordan K, Schlaepfer IR. Targeting Fat Oxidation in Mouse Prostate Cancer Decreases Tumor Growth and Stimulates Anti-Cancer Immunity. Int J Mol Sci. 2020 Dec 18; 21(24).
-
Menasche BL, Davis EM, Wang S, Ouyang Y, Li S, Yu H, Shen J. PBRM1 and the glycosylphosphatidylinositol biosynthetic pathway promote tumor killing mediated by MHC-unrestricted cytotoxic lymphocytes. Sci Adv. 2020 11; 6(48).
-
Oweida AJ, Darragh L, Phan A, Binder D, Bhatia S, Mueller A, Court BV, Milner D, Raben D, Woessner R, Heasley L, Nemenoff R, Clambey E, Karam SD. STAT3 Modulation of Regulatory T Cells in Response to Radiation Therapy in Head and Neck Cancer. J Natl Cancer Inst. 2019 12 01; 111(12):1339-1349.
-
McDaniel DK, Ringel-Scaia VM, Morrison HA, Coutermarsh-Ott S, Council-Troche M, Angle JW, Perry JB, Davis G, Leng W, Minarchick V, Yang Y, Chen B, Reece SW, Brown DA, Cecere TE, Brown JM, Gowdy KM, Hochella MF, Allen IC. Pulmonary Exposure to Magn?li Phase Titanium Suboxides Results in Significant Macrophage Abnormalities and Decreased Lung Function. Front Immunol. 2019; 10:2714.
-
Ramachandran I, Lowther DE, Dryer-Minnerly R, Wang R, Fayngerts S, Nunez D, Betts G, Bath N, Tipping AJ, Melchiori L, Navenot JM, Glod J, Mackall CL, D'Angelo SP, Araujo DM, Chow WA, Demetri GD, Druta M, Van Tine BA, Grupp SA, Abdul Razak AR, Wilky B, Iyengar M, Trivedi T, Winkle EV, Chagin K, Amado R, Binder GK, Basu S. Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma. J Immunother Cancer. 2019 10 24; 7(1):276.
-
Wilky BA. Immune checkpoint inhibitors: The linchpins of modern immunotherapy. Immunol Rev. 2019 07; 290(1):6-23.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|